Online inquiry

IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7177MR)

This product GTTS-WQ7177MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Acute lymphocytic leukemia (ALL), Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ7177MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5524MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CDP4940
GTTS-WQ14427MR IVTScrip™ mRNA-Anti-IL2RA, RO 24-7375(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RO 24-7375
GTTS-WQ13749MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ3969MR IVTScrip™ mRNA-Anti-CD3E&FCRL5, BFCR-4350-A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BFCR-4350-A
GTTS-WQ4235MR IVTScrip™ mRNA-Anti-Factor VIII substitute, BIIB031(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB031
GTTS-WQ9809MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ15524MR IVTScrip™ mRNA-Anti-TGM2, UCB-7858(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-7858
GTTS-WQ3652MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1187982
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW